in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Wacker’s Secretion Technology Studied
May 26, 2008 | Deepti Ramesh
Wacker Biotech (Jena, Germany), a wholly owned subsidiary of Wacker Chemie, says it has completed a feasibility study demonstrating that the company’s secretion technology can produce active protein comparable to that produced by mammalian cell cultures. “We believe the positive results of this study demonstrate that secreting E. coli systems can be a great tool for producing biologics in the future,” says Thomas Maier, managing director of Wacker Biotech. The study was aimed at determining the company’s efficacy of proprietary E. coli...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee